Know Cancer

or
forgot password

Autologous Stem Cell Harvesting for Waldenstrom's Macroglobulinemia


N/A
18 Years
N/A
Open (Enrolling)
Both
Lymphoma

Thank you

Trial Information

Autologous Stem Cell Harvesting for Waldenstrom's Macroglobulinemia


OBJECTIVES:

- Harvest and store adequate CD34+ stem cells from patients with Waldenstrom's
macroglobulinemia (WM) for potential future use in transplantation strategies.

- Evaluate the ability to harvest stem cells after therapy for WM (e.g.,
fludarabine-based chemotherapy) by evaluating the number of days to adequate harvest.

- Collect aliquots of stem cells for future research analysis as part of a WM database
project.

OUTLINE: Patients undergo collection of autologous stem cells beginning on day 4 or 5 and
continuing until an adequate number of stem cells are collected. Cells are then
cryopreserved.

PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Diagnosis of Waldenstrom's macroglobulinemia (WM)

- Less than 30% lymphoplasmacytoid cells in bone marrow by histopathology

- Received prior chemotherapy for WM

PATIENT CHARACTERISTICS:

- ECOG performance status 0-1

- WBC > 2,000/mm³

- Platelet count > 50,000/mm³

- LVEF ≥ 50%

- No organ dysfunction that would preclude future transplantation

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

Type of Study:

Observational

Study Design:

N/A

Outcome Measure:

Number of days to adequate stem cell harvest

Safety Issue:

No

Principal Investigator

Gwen L. Nichols, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Herbert Irving Comprehensive Cancer Center

Authority:

Unspecified

Study ID:

CDR0000487602

NCT ID:

NCT00899119

Start Date:

November 2005

Completion Date:

Related Keywords:

  • Lymphoma
  • Waldenström macroglobulinemia
  • Lymphoma
  • Waldenstrom Macroglobulinemia

Name

Location

Herbert Irving Comprehensive Cancer Center at Columbia University Medical CenterNew York, New York  10032